Business News • PR NewsWire • Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ -- U.S. FDA submission for children planned for 4Q 2019 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in...

View More : https://www.prnewswire.com:443/news-releases/dupixent-dupilumab-showed-positive-topline-results-in-phase-3-trial-of-chil...

Releted News by prnewswire

Fourdesire Launches "Plastic-free July…And More!" Campaign to Reduce Plastic Pollution and Foster Eco-friendly Lifestyle Behaviors

Barneys New York Secures $75 Million in New Capital to Facilitate Going Concern Sale Process

Dame Jayne-Anne Gadhia to Join Salesforce as UK and Ireland CEO

AT&T Invests More Than $7.2 Billion Over 8-Year Period to Boost Local Networks in Illinois

BNBuilders Turns to Autodesk to Manage Complex Construction Projects Throughout the Building Lifecycle